한글목차

신경보철 시장 규모는 2023년에 71억 4,000만 달러에 달했습니다. 이 시장은 2024-2030년의 예측 기간 중 12.75%의 CAGR로 확대하며, 2030년에는 146억 4,000만 달러에 달할 것으로 예측됩니다. 신경보철의 수요는 주로 신경질환 및 신경 손상의 유병률 증가, 난청 및 시력 저하로 고통받는 환자 증가에 기인합니다. 주요 기업 간의 R&D 활동과 첨단 기기 개발을 위한 협력 관계의 발전은 2024-2030년의 예측 기간 중 신경 보철 시장의 긍정적인 성장에 기여하는 주요 요인으로 작용할 것으로 보입니다.

신경장애와 신경손상 유병률 증가는 신경보철 시장의 큰 성장을 가속할 것으로 예상됩니다. 세계보건기구(WHO)가 2024년 4월 발표한 자료에 따르면 2021년 전 세계에서 약 1,540만 명이 척수 손상을 입었습니다. 마찬가지로 미국 척수협회(United Spinal Association)는 2022년 미국에서 연간 약 17,700명이 척수 손상 진단을 받았다고 보고했습니다. 근육과 신경을 자극하여 운동 기능을 회복시키는 신경 보철은 이러한 손상을 입은 사람들에게 매우 중요한 역할을 하고 있습니다. 신경질환, 특히 척수 손상의 발생률이 증가함에 따라 신경 보철 솔루션에 대한 수요도 증가하여 시장 확대가 가속화되고 있습니다.

근위축성측색경화증(ALS), 척수성 근위축증과 같은 운동 신경 장애와 알츠하이머병, 파킨슨병과 같은 인지 장애의 발생이 증가하면서 시장 성장을 더욱 촉진할 것으로 예상되며, 세계보건기구(WHO)의 2023년 추정에 따르면 전 세계에서 약 5,500만 명이 치매를 앓고 있다고 합니다. 치매를 앓고 있으며, 매년 1,000만 명에 가까운 신규 환자가 보고되고 있습니다. 치매의 가장 흔한 형태인 알츠하이머병이 전체 치매 환자의 60-70%를 차지합니다. 운동신경장애 환자 수는 지속적으로 증가하고 있으며, 신경보철에 대한 수요가 급증할 것으로 예상되어 예측 기간 중 시장이 크게 발전할 것으로 예상됩니다.

또한 신경보철에 대한 수요는 청각장애, 시각장애 등 감각장애까지 확대되고 있으며, 2023년 3월 세계보건기구(WHO) 데이터에 따르면 유럽에서 1억 9,000만 명 이상이 난청의 영향을 받고 있으며, 2050년까지 이 수치는 2억 3,000만 명을 넘어설 것으로 예상됩니다. 신경보철의 대표적인 유형인 인공와우는 내이의 손상된 부분을 우회하여 청신경을 직접 자극함으로써 중증의 감음성 난청 환자의 청력을 회복시키는 중요한 역할을 합니다. 청각 및 시각 장애가 더욱 보편화됨에 따라 신경보철 시장은 강력한 성장세를 보일 것으로 예상됩니다.

세계의 신경보철 시장에 대해 조사했으며, 시장의 개요와 유형별, 시술별, 기술별, 최종사용자별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 제공하고 있습니다.

목차

제1장 신경보철 시장 보고서 서론

제2장 신경보철 시장의 개요

제3장 경쟁 구도

제4장 규제 분석

• 미국
• 유럽
• 일본
• 중국

제5장 신경보철 시장의 주요 요인 분석

• 신경보철 시장 성장 촉진요인
• 신경보철 시장 성장 억제요인과 과제
• 신경보철 시장 기회

제6장 신경보철시장의 Porter's Five Forces 분석

제7장 신경보철 시장 평가

• 유형별
• 시술별
• 기술별
• 최종사용자별
• 지역별

제8장 신경보철 시장의 기업과 제품 개요

• Medtronic
• Boston Scientific Corporation
• Abbott Laboratories
• NeuroPace, Inc.
• Cochlear Ltd.
• Sonova
• NeuroSigma, Inc.
• Blackrock Neurotech
• Synchron
• LivaNova, Inc.
• MED-EL Medical Electronics
• BrainGate
• NEVRO CORP.
• Terumo Corporation
• Penumbra, Inc.
• BrainCo, Inc.
• Axoft Inc.
• Demant A/S
• Synapse Biomedical Inc.
• Cognixion, Inc.

제9장 KOL의 견해

제10장 프로젝트 어프로치

제11장 DelveInsight 소개

제12장 면책사항과 문의

영문목차

Neuroprosthetics Market by Type (Motor Prosthetics, Cognitive Prosthetics, Auditory Prosthetics/Cochlear Implants, and Visual Prosthetics/Retinal Implants), Procedure (Invasive and Non-Invasive), Technology (Deep Brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Spinal Cord Stimulation, Transcranial Magnetic Stimulation, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2030 owing the growing prevalence of neurological disorders and increasing R&D activities and collaborations to develop advanced devices.

The neuroprosthetics market was valued at USD 7.14 billion in 2023, growing at a CAGR of 12.75% during the forecast period from 2024 to 2030, to reach USD 14.64 billion by 2030. The demand for neuroprosthetics is primarily attributed to the growing prevalence of neurological disorders and nerve injuries and the rising number of patients suffering from hearing and vision loss. Increasing R&D activities and collaborations to develop advanced devices among key players are the key factors that are responsible in contributing to the positive growth of the neuroprosthetics market during the forecast period from 2024 to 2030.

Neuroprosthetics Market Dynamics:

The increasing prevalence of neurological disorders and nerve injuries is poised to drive significant growth in the neuroprosthetics market. According to data released by the World Health Organization (WHO) in April 2024, approximately 15.4 million people worldwide were living with spinal cord injuries in 2021. Similarly, the United Spinal Association reported in 2022 that around 17,700 individuals are diagnosed with spinal cord injuries annually in the United States. Neuroprosthetic devices, which restore motor function by stimulating muscles or nerves, have become crucial for individuals affected by such injuries. As the incidence of neurological conditions, especially spinal cord injuries, rises, so does the demand for neuroprosthetic solutions, accelerating market expansion.

The growing occurrence of motor neuron disorders, including amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy, as well as cognitive disorders such as Alzheimer's and Parkinson's disease, is expected to further boost market growth. WHO estimates from 2023 show that approximately 55 million people worldwide were living with dementia, with nearly 10 million new cases being reported annually. Alzheimer's disease, the most common form of dementia, accounts for 60-70% of these cases. As the number of patients with motor neuron disorders continues to rise, the need for neuroprosthetics is projected to surge, driving substantial advancements in the market over the forecast period.

Furthermore, the demand for neuroprosthetics extends to sensory impairments, such as hearing and vision loss. WHO data from March 2023 indicates that over 190 million people in Europe were affected by hearing loss, a number expected to exceed 230 million by 2050. Cochlear implants, a leading type of neuroprosthetic device, play a key role in restoring hearing for individuals with severe sensorineural hearing loss by bypassing damaged parts of the inner ear and directly stimulating the auditory nerve. As hearing and vision impairments become more prevalent, the neuroprosthetics market is expected to experience robust growth.

Source: World Health Organization, 2023

In addition to rising patient numbers, increasing research and development initiatives are expected to fuel further market expansion. For example, in April 2021, Rice University and Houston Methodist launched the Center for Translational Neural Prosthetics, focusing on restoring brain functions lost due to disease or injury.

However, certain challenges, such as the high cost of these devices and the lack of proper training in underdeveloped regions, may constrain market growth. Addressing these barriers will be key to unlocking the full potential of neuroprosthetic technologies.

Neuroprosthetics Market Segment Analysis:

Neuroprosthetics Market by Type (Motor Prosthetics, Cognitive Prosthetics, Auditory Prosthetics/Cochlear Implants, and Visual Prosthetics/Retinal Implants), Procedure (Invasive and Non-Invasive), Technology (Deep Brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Spinal Cord Stimulation, Transcranial Magnetic Stimulation, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

The spinal cord stimulation (SCS) segment is expected to hold a prominent position in the neuroprosthetics market during the forecast period, driven by the rising prevalence of chronic pain conditions, including complex regional pain syndrome (CRPS) and spinal cord injuries. With an increasing number of patients affected by failed back syndrome and CRPS, demand for SCS technology is set to grow significantly. Research has consistently demonstrated that SCS is an effective treatment for managing patients with CRPS. According to 2023 data from the National Organization for Rare Disorders, approximately 200,000 individuals in the United States are affected by CRPS annually. As the prevalence of both CRPS and spinal cord injuries continues to rise, the demand for SCS devices is increasing, thereby contributing to substantial market growth.

Recent regulatory approvals for SCS technology are further expected to propel the neuroprosthetics market. For example, in April 2024, Medtronic received approval from the U.S. Food and Drug Administration (FDA) for its Inceptiv(TM) closed-loop rechargeable spinal cord stimulator, designed to treat chronic pain. This advanced device features a closed-loop system that senses biological signals along the spinal cord, ensuring consistent delivery of physician-prescribed stimulation for improved patient outcomes. Such technological advancements from key industry players are anticipated to drive continued growth in the market.

North America is expected to dominate the overall neuroprosthetics market:

North America is projected to dominate the global neuroprosthetics market during the forecast period, primarily driven by the rising prevalence of hearing loss and neurological disorders such as Alzheimer's disease, Parkinson's disease, and depression. Additionally, increasing healthcare awareness and ongoing technological advancements from leading industry players are significantly boosting market growth in this region.

A key factor driving market expansion in North America is the growing incidence of neurological disorders. According to a report from the Centers for Disease Control and Prevention (CDC) in September 2023, approximately 6.7 million individuals aged 65 and older in the United States were living with Alzheimer's disease, with that number expected to rise to 13.9 million by 2060. The escalating prevalence of such conditions is fueling demand for neuroprosthetic devices, thereby propelling market growth.

The growing burden of hearing loss is also contributing to the region's market expansion. CDC data from November 2023 revealed that in 2021, there were 6,520 reported cases of permanent hearing loss in the United States. This rising incidence is further driving the adoption of neuroprosthetic solutions, such as cochlear implants, to address sensory impairments.

Technological innovation by key players is another factor supporting North America's market dominance. For example, in November 2022, U.S.-based brain-computer interface company Blackrock Neurotech introduced Neuralace(TM), a next-generation neural interface. This advanced device, designed with diverse materials and patterns, connects with large areas of the brain's surface, enabling complex functions without the need for external assistive technologies. Neuralace offers groundbreaking solutions for vision and memory restoration, performance prediction, and the treatment of mental health disorders, underscoring the role of innovation in driving market growth.

Meanwhile, the Asia-Pacific region holds significant growth potential for the neuroprosthetics market. This expansion can be attributed to improving healthcare infrastructure, rising disposable incomes, and increasing incidences of hearing loss. According to a 2021 report from the World Health Organization (WHO), around 80% of people with disabling hearing loss reside in low- and middle-income countries, with over 25% of individuals aged 60 and older affected. As the region's economies develop and healthcare systems improve, the demand for neuroprosthetic devices is expected to rise, fueling further market growth in Asia-Pacific.

Neuroprosthetics Market Key Players:

Some of the key market players operating in the neuroprosthetics market include Medtronic, Boston Scientific Corporation, Abbott Laboratories, NeuroPace, Inc., Cochlear Ltd., Sonova, NeuroSigma, Inc., Blackrock Neurotech, Synchron, LivaNova, Inc., MED-EL Medical Electronics, BrainGate, NEVRO CORP., Terumo Corporation, Penumbra, Inc., BrainCo, Inc., Axoft Inc., Demant A/S, Synapse Biomedical Inc., Cognixion, Inc., and others.

Recent Developmental Activities in the Neuroprosthetics Market:

• In February 2024, Boston Scientific Corporation announced that the U.S. Food and Drug Administration (FDA) approved the WaveWriter(TM) SCS Systems for the treatment of chronic low back and leg pain. This system assists physicians in delivering individualized care for a broad range of lower back pain issues, allowing for tailored treatment strategies to address diverse patient needs.
• In January 2024, Abbott Laboratories announced that it granted FDA approval to market the Liberta RC(TM) DBS system. Liberta is the smallest rechargeable deep brain stimulation (DBS) device equipped with remote programming capabilities, designed to treat individuals with movement disorders such as Parkinson's disease and essential tremor.
• In March 2021, Second Sight Medical Products, a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, received the US Food and Drug Administration (FDA) approval for the Argus 2s Retinal Prosthesis System.
• In January 2021, Boston Scientific Corporation received FDA approval for its fourth-generation Vercise Genus Deep Brain Stimulation (DBS) System used to treat symptoms in patients with advanced Parkinson's disease.

Key Takeaways from the Neuroprosthetics Market Report Study

• Market size analysis for current Neuroprosthetics Market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the Neuroprosthetics market.
• Various opportunities available for the other competitors in the Neuroprosthetics Market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current Neuroprosthetics market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for Neuroprosthetics market growth in the coming future?

Target Audience who can be benefited from this Neuroprosthetics Market Report Study

• Neuroprosthetics product providers
• Research organizations and consulting companies
• Neuroprosthetics related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in Neuroprosthetics
• Various end-users who want to know more about the Neuroprosthetics Market and the latest technological developments in the Neuroprosthetics Market.

Frequently Asked Questions for the Neuroprosthetics Market:

1. What are Neuroprosthetics?

• A neuroprosthetic is a kind of device that can ameliorate the input or output of a neural system. Neuroprosthetics encompass a variety of artificial devices or systems that can be used to enhance the motor, sensory, cognitive, visual, auditory, and communicative deficits that arise from acquired brain injuries.

2. What is the market for Neuroprosthetics?

• The Neuroprosthetics Market was valued at USD 7.14 billion in 2023, growing at a CAGR of 12.75% during the forecast period from 2024 to 2030 to reach USD 14.64 billion by 2030.

3. What are the drivers for the Neuroprosthetics market?

• The neuroprosthetics market is slated to witness prosperity owing to factors such as the growing prevalence of neurological disorders and nerve injuries and the rising number of patients suffering from hearing and vision loss. Increasing R&D activities and collaborations to develop advanced devices among key players are the key factors that are responsible for contributing to the positive growth of the neuroprosthetics market during the forecast period from 2024 to 2030.

4. Who are the key players operating in the Neuroprosthetics market?

• Some of the key market players operating in the neuroprosthetics market include Medtronic, Boston Scientific Corporation, Abbott Laboratories, NeuroPace, Inc., Cochlear Ltd., Sonova, NeuroSigma, Inc., Blackrock Neurotech, Synchron, LivaNova, Inc., MED-EL Medical Electronics, BrainGate, NEVRO CORP., Terumo Corporation, Penumbra, Inc., BrainCo, Inc., Axoft Inc., Demant A/S, Synapse Biomedical Inc., Cognixion, Inc., and others.

5. Which region has the highest share in the Neuroprosthetics market?

• North America is expected to dominate the overall neuroprosthetics market during the forecast period from 2024 to 2030. This dominance can be attributed to the rising prevalence of hearing loss and neurological disorders such as Alzheimer's disease, Parkinson's disease, and depression. Additionally, increasing healthcare awareness and technological innovations spearheaded by leading industry players are significantly contributing to market growth in North America.

Table of Contents

1. Neuroprosthetics Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Neuroprosthetics Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Neuroprosthetics Market Key Factors Analysis

• 5.1. Neuroprosthetics Market Drivers
  • 5.1.1. The growing prevalence of neurological disorders and nerve injuries
  • 5.1.2. Rising number of patients suffering from hearing and vision loss
  • 5.1.3. Increasing R&D activities and collaborations to develop advanced devices among key players
• 5.2. Neuroprosthetics Market Restraints and Challenges
  • 5.2.1. The high cost of these devices
  • 5.2.2. Lack of proper training in poor developed countries
• 5.3. Neuroprosthetics Market Opportunity
  • 5.3.1. Integration of robotic-assisted implantation
  • 5.3.2. Adoption of minimally invasive surgeries and smart implants

6. Neuroprosthetics Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Neuroprosthetics Market Assessment

• 7.1. By Type
  • 7.1.1. Motor Prosthetics
  • 7.1.2. Cognitive Prosthetics
  • 7.1.3. Auditory Prosthetics/Cochlear Implants
  • 7.1.4. Visual Prosthetics/Retinal Implants
• 7.2. By Procedure
  • 7.2.1. Invasive
  • 7.2.2. Non-Invasive
• 7.3. By Technology
  • 7.3.1. Deep Brain Stimulation
  • 7.3.2. Vagus Nerve Stimulation
  • 7.3.3. Sacral Nerve Stimulation
  • 7.3.4. Spinal Cord Stimulation
  • 7.3.5. Transcranial Magnetic Stimulation
  • 7.3.6. Others
• 7.4. By End-User
  • 7.4.1. Hospitals and Clinics
  • 7.4.2. Ambulatory Surgical Centers
  • 7.4.3. Others
• 7.5. By Geography
  • 7.5.1. North America
    • 7.5.1.1. United States Neuroprosthetics Market Size in USD million (2021-2030)
    • 7.5.1.2. Canada Neuroprosthetics Market Size in USD million (2021-2030)
    • 7.5.1.3. Mexico Neuroprosthetics Market Size in USD million (2021-2030)
  • 7.5.2. Europe
    • 7.5.2.1. France Neuroprosthetics Market Size in USD million (2021-2030)
    • 7.5.2.2. Germany Neuroprosthetics Market Size in USD million (2021-2030)
    • 7.5.2.3. United Kingdom Neuroprosthetics Market Size in USD million (2021-2030)
    • 7.5.2.4. Italy Neuroprosthetics Market Size in USD million (2021-2030)
    • 7.5.2.5. Spain Neuroprosthetics Market Size in USD million (2021-2030)
    • 7.5.2.6. Rest of Europe Neuroprosthetics Market Size in USD million (2021-2030)
  • 7.5.3. Asia-Pacific
    • 7.5.3.1. China Neuroprosthetics Market Size in USD million (2021-2030)
    • 7.5.3.2. Japan Neuroprosthetics Market Size in USD million (2021-2030)
    • 7.5.3.3. India Neuroprosthetics Market Size in USD million (2021-2030)
    • 7.5.3.4. Australia Neuroprosthetics Market Size in USD million (2021-2030)
    • 7.5.3.5. South Korea Neuroprosthetics Market Size in USD million (2021-2030)
    • 7.5.3.6. Rest of Asia-Pacific Neuroprosthetics Market Size in USD million (2021-2030)
  • 7.5.4. Rest of the World (RoW)
    • 7.5.4.1. Middle East Neuroprosthetics Market Size in USD million (2021-2030)
    • 7.5.4.2. Africa Neuroprosthetics Market Size in USD million (2021-2030)
    • 7.5.4.3. South America Neuroprosthetics Market Size In USD Million (2021-2030)

8. Neuroprosthetics Market Company and Product Profiles

• 8.1. Medtronic
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Boston Scientific Corporation
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Abbott Laboratories
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. NeuroPace, Inc.
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Cochlear Ltd.
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Sonova
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. NeuroSigma, Inc.
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Blackrock Neurotech
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Synchron
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. LivaNova, Inc.
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. MED-EL Medical Electronics
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. BrainGate
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. NEVRO CORP.
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Terumo Corporation
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Penumbra, Inc.
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. BrainCo, Inc.
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Axoft Inc.
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. Demant A/S
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Synapse Biomedical Inc.
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. Cognixion, Inc.
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us